OCULAR THERAPEUTIX, INC Derivative Liability, Noncurrent
OCULAR THERAPEUTIX, INC (OCUL) had Derivative Liability, Noncurrent of $10.91 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-03
- 2026-06-30: Derivative Liability, Noncurrent $10.91M.
- 2026-03-31: Derivative Liability, Noncurrent $12.07M.
- 2025-12-31: Derivative Liability, Noncurrent $13.90M.
- 2025-09-30: Derivative Liability, Noncurrent $14.96M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-06-30 | $10.91M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $12.07M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $13.90M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $14.96M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $14.02M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $13.85M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $13.25M 10-K · filed 2026-02-05 |
| 2024-09-30 | $14.46M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $22.08M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $19.62M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $29.99M 10-K · filed 2025-03-03 |
| 2023-09-30 | $24.02M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $11.78M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $12.91M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $6.35M 10-K · filed 2024-03-11 |
| 2022-09-30 | $11.59M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $10.46M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $13.23M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $20.19M 10-K · filed 2023-03-06 |
| 2021-09-30 | $36.06M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $59.90M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $73.30M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $98.31M 10-K · filed 2022-02-28 |
| 2020-09-30 | $28.76M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $32.53M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $15.53M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $12.12M 10-K · filed 2021-03-11 |
| 2019-09-30 | $9.10M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $13.07M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $11.46M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |